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Abstract
Background: Tuberous sclerosis complex (TSC) is an autosomal dominant disorder characterized by hamartomas in
multiple organs associated with germline mutations in TSC1 and TSC2, including exonic, intronic, or mosaic
mutations. Gastrointestinal (GI) tract Lymphangioleiomyomatosis (LAM) is an extremely rare manifestation of TSC,
with few reported cases. Herein, we aimed to determine the driver mutation, pathogenesis, and relationship of
germline and somatic mutations of LAM through whole-genome sequencing (WGS) of the tumor and blood
samples and whole transcriptome sequencing (WTS) analysis.
Case presentation: A nine-year-old girl with a full-blown TSC presented with abdominal masses detected during a
routine check-up. Resected intestinal masses were diagnosed as LAM by thorough pathological examination.
Interestingly, the LAM presented a somatic TSC2 gene mutation in exon 24 (p.R905W, c.C2713T), and the patient
had intron retention by a novel germline mutation in the intron region of TSC2 (chr16:2126489, C > G).
Conclusion: Our case suggests that intron retention by a single nucleotide intronic mutation of TSC2 is sufficient to
develop severe manifestations of TSC, but the development of LAM requires an additional somatic oncogenic
mutation of TSC2.
Keywords: Intron retention, Lymphangioleiomyomatosis, Germline mutation, Somatic mutation, Perivascular
epithelioid cell tumor (PEComa), Tuberous sclerosis complex
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: hyunjulee@gist.ac.kr; shparknp@snu.ac.kr
2School of Electrical Engineering and Computer Science, Gwangju Institute
of Science and Technology, 123 Cheomdangwagi-ro, Buk-gu, Gwangju
61005, Republic of Korea
1Department of Pathology, Seoul National University Hospital, Seoul National
University College of Medicine, 103 Daehak-ro, Jongno-gu, Seoul 03080,
South Korea
Full list of author information is available at the end of the article
Han et al. Diagnostic Pathology           (2021) 16:83 
https://doi.org/10.1186/s13000-021-01138-8
Background
Herein, we report a case of Tuberous sclerosis complex
(TSC) with hamartomas in multiple organs and gastro-
intestinal lymphangioleiomyomatosis (GI LAM). TSC is
an autosomal dominant disorder characterized by
hamartomas in multiple organs, seizure disorders, men-
tal retardation, and a reported prevalence of 1/6000 to
1/10,000 live births [1, 2]. TSC1 (9q34) and TSC2
(16p13), both known tumor suppressors, are the causa-
tive genes. Mutations in these genes result in dysregula-
tion of the mammalian target of rapamycin (mTOR
pathway) [3]. To date, more than 1000 mutations have
been reported in TSC1 and TSC2 [4]. However, 10–15%
of clinically diagnosed TSC have no known identifiable
mutations and could be attributed to mutations in the
promoter, enhancer, or intron region, as well as mosai-
cism or technical problems [4–6]. Tyburczy et al. have
identified mutations in 85% (45 of 53) of patients with
TSC in whom no mutations were initially identified by
conventional testing [6]. Most of these mutations can be
attributed to mosaicism (58%) and intronic mutations
(40%) [6]. TSC patients with mosaicism tend to present
less severe symptoms, consistent with the gene dosage
effect [5]. Intronic mutations are rare and remain un-
detected with whole-exome sequencing (WES) and with
whole-genome sequencing (WGS), special analysis algo-
rithms are still required.
Lymphangioleiomyomatosis (LAM) is a rare neo-
plasm. Notably, it is a type of perivascular epithelioid
cell tumor (PEComa), characterized by aberrant pro-
liferation of smooth muscle-like cells that express
melanocytic (HMB45 and Melan-A) and smooth
muscle markers (smooth muscle actin, desmin, and
caldesmon), as well as melanocyte inducing transcrip-
tion factor/ Microphthalmia-Associated Transcription
Factor (MITF) [7]. There are two identified subtypes:
sporadic-LAM (S-LAM) and TSC-related LAM (TSC-
LAM). Both are induced by TSC1 or, more com-
monly, TSC2 gene mutations [8]. The gastrointestinal
(GI) tract is a rare site for LAM.
By employing WGS and transcriptome studies, we
detected germline intronic and somatic TSC2 gene
mutations in this patient. Typically, intron retention
has been considered “noise” as it is technically chal-
lenging to detect and quantify transcripts with
retained introns globally [9]. However, we hypothesize
that intron retention of the TSC2 protein by intron
mutation could be a driver mutation of TSC and that
TSC2 somatic mutation is responsible for the devel-
opment of LAM. The percentage of TSC1/TSC2
second-hit tumors is 65.1% of TSC-related tumors
[10]. Herein, we focus on the tumorigenic mechanism
of intron retention and second hit somatic mutation
of TSC2 observed in LAM.
Case presentation
A nine-year-old girl presented with abdominal masses
detected in an abdominal sonogram during follow-up
check for her TSC manifestations and any tumor
development.
Prenatal ultrasound first detected nodules in her heart.
Under possibility of TSC, ophthalmology and brain MRI
were performed after birth and revealed hamartomas in
eyes and intraventricular nodules, suggesting subependy-
mal giant cell astrocytoma (SEGA). She was diagnosed
with TSC through genetic test conducted at outside hos-
pital. Myoclonic seizures were observed when she was
approximately 100 days old. Furthermore, she presented
mental retardation and intermittent febrile or afebrile
generalized tonic-clonic seizures, with an abnormal elec-
troencephalogram. She was prescribed an antiepileptic
drug and was under close observation. Abdominopelvic
and chest computed tomography scans showed multiple
small nodules in both kidneys, lungs, and intestines,
from the cecum to the ascending colon (Fig. 1). She then
underwent laparoscopy-assisted right hemicolectomy.
No events related to GI LAM occurred during the 2-
year postoperative follow-up period.
Pathology and immunohistochemistry
On gross examination, multiple nodules were observed
along the cecum wall, up to the ascending colon. The
largest nodule was 6.1 cm (Fig. 2). The nodules were
well-demarcated, tan-to-white, and had solid
consistency, with hemorrhage and necrosis. Microscop-
ically, the tumor was composed of smooth muscle-like
spindle cells, with bland-looking elongated nuclei and
eosinophilic cytoplasm arranged in a fascicular pattern.
Tumor cells were distributed around the slit-like vascu-
lar spaces lined by flattened endothelial cells. Focal ne-
crosis was observed in the center of the largest nodule,
and the mitotic index was 2/50 high power fields. In
total, 4 out of the 17 lymph nodes presented metastatic
LAM.
Immunohistochemical staining was performed on an
immunostaining system (BenchMark ULTRA system,
Ventana-Roche, Mannheim, Germany) using primary
antibodies, including HMB45 (A: 200, Millipore, Temec-
ula, US), D2–40 (1: 50, DAKO, Glostrup, Denmark),
smooth muscle actin (SMA, 1:500, DAKO), c-kit
(CD117, 1: 500, Abcam, Cambridge, UK), CD34 (1:200,
DAKO), caldesmon (1: 1000, DAKO), desmin (1:200,
DAKO), myogenin (1: 500, DAKO), Melan-A (1: 1000,
Cell Marque, Rocklin, USA), and Ki-67 (1: 100, DAKO)
(Table 1). Appropriate positive controls were included,
and primary antibodies were omitted from negative
controls.
The tumor cells expressed HMB45, D2–40, GLUT-1,
and SMA but were negative for c-kit and CD34, both
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specific GI stromal tumor markers (GIST) (Fig. 2).
Moreover, tumor cells were negative for caldesmon, des-
min, myogenin, and Melan-A and S-100. We ruled out
leiomyomatosis by HMB45 expression in our tumor and
also excluded malignant melanoma by negative for
Melan-A and S-100 in our tumor. The Ki-67 labeling
index was 10.0%. Immunostaining with D2–40
highlighted endothelial cells lining the slit-like channels.
Hence, the lesion was diagnosed as a LAM.
Preprocessing and analysis of WGS and WTS
Representative tumor areas with at least 90% tumor cell
content were outlined for macrodissection on
hematoxylin-eosin-stained fresh frozen tissue sections.
DNA/RNA extraction was performed from the freshly
frozen tissue and patient blood using the Maxwell® RSC
DNA/RNA FFPE Kit (Promega, USA).
WGS data were generated using the TruSeq DNA
PCR Free library kit and Illumina platform, which had a
150 bp read length, 408 bp fragment length median, and
1,450,195,688 total reads. The paired-end sequence was
mapped to the human genome (original GRCh37 from
NCBI, February 2009) using Isaac aligner (iSAAC-
04.18.11.09). The Isaac aligner identifies and selects the
foremost mapping candidates using a 32-mer seed-based
search. The 3 end with low quality and adapter se-
quences were trimmed from the alignment. The Isaac
aligner generates a binary alignment output bam file that
includes sorted and duplicate-marked data.
WTS data were produced using the SureSelectXT
RNA Direct library kit and NovaSeq 6000 platform, cre-
ating a 101 bp read length and 161,213,862 total reads.
The STAR aligner was used for RNA-Seq data to create
a sorted bam file, and its index was created using Sam-
tools v1.9. RSEM [11], with edgeR [12] steps performed
to obtain the expression values. The fastq files of the
WGS and WTS samples had high Phred quality scores.
For tumor WGS, normal blood WGS, and tumor WTS
samples, 97.2, 97.6, and 98.42% of the bases had quality
scores > 20 for tumor WGS, normal WGS, and tumor
WTS samples, respectively.
Detection of somatic mutation
Somatic mutations for single nucleotide variants (SNVs)
and insertions and deletions (INDELs) were detected
using the Genome Analysis Toolkit (GATK) Mutect2
v4.1.4.1 [13] with default parameters. All the variants
were annotated by ANNOVAR (https://doc-openbio.
readthedocs.io/projects/annovar/en/latest/) [14].
Fig. 1 A Brain MRI showing an ovoid, enhancing mass at the right lateral ventricle (arrow). B Abdominal CT scan showing multiple low-
attenuated foci in both kidneys (arrows). C Ultrasonography findings showing multiple low echoic nodules along the bowel wall. D Abdominal
CT scan showing multiple enhancing masses along the ascending colon wall (arrows). MRI, magnetic resonance imaging; CT,
computed tomography
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By employing the WGS data, we detected 12 genes
with nonsynonymous somatic mutations and but only 2
mutations (MST1: p.E261Q, and TSC2: p.R905W) are
pathogenic (Supplementary Table 1). Among them,
TSC2 had a somatic hotspot mutation (p.R905W,
c.C2713T) (Fig. 3A). We assessed whether this deleteri-
ous variant in TSC2 was expressed in mRNA using
RNA-Seq data from the tumor sample. STAR 2-PASS
[15] was used to create the bam file from the RNA-Seq
data, and the reads were visualized using IGV [16]. In
Fig. 2 A The tumor is well-demarcated, with masses along the intestinal wall. B, C On sectioning and low power view, the tumor appears to
replace the proper muscle layer of the cecum with central suppurative necrosis. D High power view of the tumor shows spindle shape
mesenchymal cells with slit-like lymphatic channels. The tumor cells show little nuclear atypia. E, F The tumor cells are positive for HMB45 and
D2–40. G Tumor is focally positive for smooth muscle actin (SMA). H Ki-67 index is 7.0%. Above mentioned pathological and
immunohistochemical features are consistent with LAM. (A, B: gross picture, C, D: H&E, E: HMB45, F: D2–40, G: SMA, H: Ki-67, lower bar: C = 2.5
mm, D = 200 μm, E = 5mm, F,G: 200 μm, H = 100 μm). LAM, lymphangioleiomyomatosis
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total, 570 reads were mapped in the concerned region,
and 390 (variant allele frequency [VAF]: 68.0%) had vari-
ant sequences.
Detection of germline mutation
GATK Haplotypecaller [17] was used to identify germ-
line mutations from the WGS bam of normal data. To
ensure a high confidence germline mutation, we per-
formed a VariantRecalibrator step of GATK and used
the vcf files including dbsnp_138.hg19.vcf [18], hapmap_
3.3.hg19.sites.vcf [19], 1000G_omni2.5.hg19.sites.vcf [20],
1000G_phase1.snps.high_confidence.hg19.sites.vcf [21],
and Mills_and_1000G_gold_standard.indels.hg19.sites.vcf
[22], which were obtained from the GATK resource
bundle.
In the present patient with TSC, we detected a novel
TSC2 germline mutation in the TSC2 intron region, next
to the acceptor site (chr16:2126489, C > G). This variant
had not been previously reported in ClinVar [23]. We
identified that 207 out of 216 reads (VAF: 96%) were
mapped to this germline mutation site.
A previously reported mutation at the same intron but
into a different nucleotide (NM_000548.4 (TSC2):
c.2743-3C > A) was observed in assembly GRCh37
(https://www.ncbi.nlm.nih.gov/clinvar/23291215/).
As reads in the RNA-Seq data were mapped to the in-
tron region, iREAD and IRFinder tools were used to de-
tect intron retention. By employing these two tools,
intron retention was detected in the chr16:2126258–
2,126,491 region, where the germline mutation occurred
(Fig. 3B). For comparison, we downloaded the RNA-Seq
data of patients with sarcoma from The Cancer Genome
Atlas (TCGA) to confirm that this event did not occur
randomly. No intron retention was detected in the
chr16:2126258–2,126,491 region on analyzing 256 sam-
ples with IRFinder (Fig. 3B). We postulate that this
Table 1 Primary antibodies used in this study
Antibody Dilution Antigen retrival Source
HMB45 1: 200 Ventana CC1 100 °C Milipore, Temecula, US
Melan-A (Mart-1) 1: 1000 Ventana CC1 100 °C Cell Marque, Rocklin, US
D2–40 1: 50 Ventana CC1 100 °C DAKO, Glostrup, Denmark
Phosphorylated mTOR 1: 100 Ventana CC1 100 °C Cell signaling, Boston, US
C-Kit 1: 500 Ventana CC1 100 °C Abcam, Cambridge, UK
SMA 1: 500 Ventana CC1 100 °C DAKO, Glostrup, Denmark
CD34 1: 200 Ventaan CC1 100 °C DAKO, Glostrup, Denmark
Caldesmon 1: 1000 Ventaan CC1 100 °C DAKO, Glostrup, Denmark
Desmin 1: 200 Ventaan CC1 100 °C DAKO, Glostrup, Denmark
Myogenin 1: 500 Ventaan CC1 100 °C DAKO, Glostrup, Denmark
Ki-67 1: 100 Ventana CC1 100 °C DAKO, Glostrup, Denmark
Fig. 3 A Somatic mutation of in TCS2. One TSC2 missense somatic mutation (p.R905W) was detected by WGS. B Intron region of TCS2 with a
novel germline mutation displayed by IGV. The RNA-Seq reads in the intron region with a novel germline mutation next to the acceptor site
(chr16:2126489, C > G) are retained between exons 24 and 25. The first and second panels show the intron region of the patient with TSC
investigated in this study and a patient with sarcoma from TCGA, respectively. TSC, Tuberous sclerosis complex; WGS, whole-genome sequencing
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intron retention did not appear randomly and that the
nearby acceptor site germline mutation might affect the
mRNA splicing mechanism.
Detection of intron retention
iREAD [22] and IRFinder [24] were used to identify in-
tron retention from RNA-Seq fastq data. We used the
default parameters for the two tools, except for the en-
tropy score of iREAD. The default threshold was strictly
set in the iREAD package. We lowered the entropy score
marginally, from 0.9 to 0.85, to detect more candidate
IR.
We obtained the trimmed mean of M-values (TMM)
of genes with edgeR. The TMM expression value of the
TSC2 gene was 28,576, which was 7.4-fold higher than
the average of two standard samples (TMM: 3857).
For reverse transcriptase-polymerase chain reaction
(RT-PCR), RNA was extracted from the peripheral blood
buffy coat and tumor (lymphangioleiomyoma) of this pa-
tient and the peripheral blood buffy coat of two healthy
(negative) controls. Primer sets were designed to detect
TSC2 gene-splicing region in the intron between the
exon 24 and exon 25 (Forward primer: GTCATAGCCA
TGTGGTTCA, Reverse primer: TCTTGGGTCTCTCG
TTGA). RT-PCR of this patient’s peripheral blood and
tumor RNA revealed the intron retention products at
530 bp and splicing products at 163 bp, but healthy con-
trols showed splicing products at 163 bp only (Fig. 4).
Discussion and conclusions
TSC is an autosomal dominant disorder caused by gen-
etic alterations in TSC1 at 9p34 (22%) and TSC2 at
16p13 (63%), with no mutation identified in about 15%
of patients [3]. TSC1 and TSC2 encode two tumor sup-
pressor proteins: hamartin and tuberin. Inactivating mu-
tations in either gene fail to inhibit the mTOR pathway
and lead to constitutive activation of mTORC1 and dys-
regulation of downstream molecules, driving uncon-
trolled cell growth and proliferation; this results in the
formation of either hamartomas or benign tumors in
multiple organs, including the skin, eyes, heart, kidneys,
and brain [3, 7, 25].
LAM is a rare neoplasm that belongs to the family of
PEComas [26]. Notably, LAM is six times more common
in females than males, and the average age of patients is
42.4 years. The relationship between TSC and LAM is
well established. Pulmonary LAM and renal angiomyoli-
pomas are common manifestations of TSC, occurring in
80 and 70% of TSC patients, respectively [1, 27]. Somatic
mutations have been detected in sporadic LAMs
(https://databases.lovd.nl/shared/diseases/00317).
In patients with TSC, GI manifestations of LAM are
infrequent, and only two cases have been reported [28,
Fig. 4 Agarose gel electrophoresis of RT-PCT using primer sets designed to detect TSC2 gene-splicing region of the intron between exon 24 and
exon 25 (Forward primer: GTCATAGCCATGTGGTTCA, Reverse primer: TCTTGGGTCTCTCGTTGA). RT-PCR with RNA from our patient’s peripheral
blood buffy coat and tumor (lymphangioleiomyoma) revealed the intron retention product at 530 bp and splicing product at 163 pp., but
negative controls (RNA from peripheral blood buffy coat of two healthy controls) showed splicing product at 163 bp only
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29]. One patient had a germline frameshift mutation in
TSC2 (p.K69Nfs*37). The presence of somatic mutations
has not been investigated in the remaining patients.
The diagnosis of LAM remains challenging owing to
its rarity in extrapulmonary sites [28, 29]. Leiomyomato-
sis, GIST, and melanoma are the differentials in the
present case. Both LAM and leiomyomatosis present as
multiple nodules along the bowel walls and show
smooth muscle cell proliferation with the expression of
smooth muscle markers. GIST comprises spindle and
epithelial cells, with c-kit, CD34, or Dog1 expressions.
Notably, the melanocytic marker, HMB-45, helps distin-
guish LAM from leiomyomatosis and GIST, as LAM is
100% immunoreactive for HMB-45, whereas the other
two entities are not [30].
In women with TSC, the prevalence of TSC-LAM is
34%; however, the estimated prevalence of S-LAM is ap-
proximately 10,000 patients worldwide, which is consid-
erably less than that of TSC-LAM [31, 32]. Both S-LAM
and TSC-LAM are associated with mutations in TSC1
and, more commonly, in TSC2 genes [33]. Through
WGS, we identified a somatic gene mutation, p.R905W
(c.C2713T), in the TSC2 region (of chromosome 16p13).
Although this variant has been reported in many individ-
uals with TSC, functional and experimental studies, as
well as computational prediction algorithm studies in-
cluded in ANNOVAR [14], have shown that this muta-
tion is pathogenic as it affects protein function [34].
Arginine at codon 905 is a critical amino acid for the
function of tuberin, and two missense mutations,
2714G > A R905Q and 2713C > T R905W in TSC2, have
been reported at this codon. Both variations influence
the mTOR signaling pathway, affecting cell proliferation,
migration, survival, and metabolism [7]. Alteration into
different amino acids in the same codon results in vary-
ing severity among phenotypes. The R905Q mutation
was detected in TSC families with a relatively mild
phenotype (normal cognition with no SEGA or epilepsy)
[35]. The R905W mutation was found in sporadic TSC
and manifested with severe symptoms. According to
an article by Sancak et al, all six patients with the
R905W mutation presented cortical tubers and SEGA,
cognitive impairment, neurologic symptoms, and add-
itional TSC features [36]. Our patient showed a somatic
missense mutation (R905W) in LAM and a novel germ-
line intronic mutation (chr16:2126489, C > G), with se-
vere neurological symptoms and multi-organ
hamartomas. A known intronic mutation at the same
site changed to a different nucleotide (NM_000548.5:
c.2743-3C > A, https://www.ncbi.nlm.nih.gov/clinvar/
variation/49229/), which affects gene splicing. This vari-
ant is not present in population germline databases.
When we performed splice site prediction using
“Berkeley Drosophila Genome Project, splice site
prediction by neural network” [37], this variant was pre-
dicted to affect normal splice donor site with the 0.99
prediction score. The novel germline intron mutation
found in our case is considered a pathogenic variant
with moderate evidence of pathogenicity in TSC.
We provided both RNAseq and RT-PCR confirmation
of intron retention. It is justified that the two different
methods for the detection of intron retention are con-
sistent. Of note, RNA analysis does not necessarily dem-
onstrate loss of normal TSC2 function, which negatively
regulates mTOR signaling. However, intron retention
has the potential to cause loss of function, consistent
with disease mechanisms.
Recent studies have reported that approximately 20%
of PEComas also have a transcription factor E3 (TFE3)
mutation. PEComas harboring TFE3 gene rearrangement
have been previously reported, presenting an epithelioid
appearance, weak or no expression of smooth muscle
markers, and robust nuclear staining of TFE3 protein
[38, 39]. In the present case, TFE3 rearrangement was
not observed. Moreover, TFE3 rearrangements and
TSC2 mutations are known to be mutually exclusive
[40]. Cutaneous PEComas do not harbor TFE3 rear-
rangements, and the occurrence of TFE3 rearrangement
might vary among organs that develop tumors [41].
A novel intron heterozygous mutation in TSC2 (chr16:
2126489, C > G) was detected through WGS and RNA
sequencing. Intron retention is an alternative splicing
method [42] and plays a regulatory role in neuronal dif-
ferentiation and neurological diseases [43]. Two different
intron retentions of TSC2 have been reported in patients
with TSC (chr16:2106052, C > T and chr16:2126489,
C > A) [44, 45]. Different mutations at the same acceptor
site of intron have been reported as possibly pathogenic
(chr16:2126483,C > G) [46]. Intron retention by intronic
mutation of TSC2 might contribute to our patient’s TSC
pathogenesis with multiple hamartomas; however, it re-
mains unclear whether the germline mutation of TSC2
is pathogenic, given that TSC2 was overexpressed. As
TSC2 is a tumor suppressor, it needs to be underex-
pressed to be considered a pathogenic mutation. There-
fore, further evaluation of the potential biological effects
of intron retention in TSC is required.
GI PEComas show a variable spectrum of biological
behavior. Folpe et al. have reported that clinically malig-
nant PEComas typically have infiltrative growth patterns,
large tumor size (> 5 cm), high nuclear grade, tumor ne-
crosis, increased mitotic activity (> 1/50 HPF), and lym-
phovascular invasion [30]. A recent study regarding GI
PEComas has reported that this tumor demonstrates
malignant behavior significantly associated with marked
nuclear atypia, diffuse pleomorphism, and mitosis ≥2/10
HPF [47]. The present patient presented a tumor ex-
ceeding 5 cm in size, infiltrative growth, tumor necrosis,
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a mitotic index of 2/50 HPF, and a Ki-67 labeling index
of 10%, consistent with malignancy. Additionally, lymph
node metastasis was detected. Previous reports have sug-
gested that surgical resection is the best treatment strat-
egy. Considering the genetic etiology of LAM affecting
the mTOR pathway, mTOR inhibitors can be a treat-
ment of choice. The mTOR inhibitor rapamycin has sev-
eral advantages in patients with LAM, stabilizing lung
function and improving quality of life. However, the dis-
continuation of therapy results in disease progression [7,
48].
In conclusion, we presented a case of a TSC patient
with extrapulmonary LAM in addition to classic TSC
triads. We identified a novel TSC2 germline intronic
mutation (chr16:2126489, C > G) and a second hit som-
atic TSC2-mutation in exon 24 (p.R905W, c.C2713T) in
the patient’s blood and tumor samples. LAM diagnosis
and treatment can be challenging; nevertheless, it is es-
sential to be aware of the association between TSC2 mu-
tations and LAM. Our findings provide clues for the
repair and prevention of TSC and suggest that intron re-
tention by intronic mutation of TSC2 is sufficient to de-
velop severe TSC manifestations; however, the
development of LAM requires an additional somatic
oncogenic mutation. Future multi-omics studies need to
elucidate the precise pathogenesis and tumorigenesis of
TSC and establish a suitable treatment strategy for this
disease.
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